Mobile website
Archive > Volume 29 Issue 9 > 2022,29(9):781-790. DOI:10.3872/j.issn.1007-385X.2022.09.001 Prev Next
Expert Forum
Immune cell therapies for solid tumors: an overview of challenges and counter measures
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
In recent years, T-lymphocyte-based immune cell therapies have achieved remarkable progress in hematologic tumors and some solid tumors. However, there still remain many challenges in immune cell therapies for solid tumors, such as antigen heterogeneity, immune evasion, poor immune cell infiltration, immunosuppressive microenvironment, metabolic obstructive microenvironment and T cell exhaustion, limiting further improvement in immune cell therapies for solid tumors. The effectiveness of immune cells in solid tumor therapy can be efficiently improved by searching for new antigens, designing multi-target CARs, overexpressing chemokine receptors and cytokines, knocking down inhibitory signaling molecules, enhancing T cell metabolic capacity, combining immune checkpoint inhibitors and epigenetic modifications. This article reviews systematically the current status of research, challenges and solution strategies of immune cell therapies for solid tumors, such as tumor-infiltrating lymphocyte (TIL) therapy, TCR-T (T cell receptor-engineered T) cell therapy and CAR-T (chimeric antigen receptor T) cell therapy.
Keywords:
Project Supported:
Clc Number:
